Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of volanesorsen in familial chylomicronemia syndrome
NL-OMON42059Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary chylomicronemia (FCS) comparing Volanesorsen with Placebo (2 arms). Primary endpoint: Percent change in fasting triglycerides from baseline. Started Jul 2015; status: active, not recruiting.
02
Drugs
volanesorsen
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on NL-OMON42059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42059.